Skip to main content

Table 5 Adverse events

From: Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain

  N Day 1 Day 8 Day 15 p-valuea
Sleepiness 45     0.004
 Mean ± SD 1.2 ± 0.7 0.9 ± 0.6 0.73 ± 0.8
 Median (range) 1 (0 - 3) 1 (0 - 2) 1 (0 - 3)
vs. day 1b   n.s. <0.05
Nausea 49     0.87
 Mean ± SD 0.4 ± 0.8 0.4 ± 0.7 0.3 ± 0.6
 Median (range) 0 (0 - 3) 0 (0 - 3) 0 (0 - 2)
Vomit 49     0.66
 Mean ± SD 0.1 ± 0.6 0.2 ± 0.6 0.1 ± 0.5
 Median (range) 0 (0 - 3) 0 (0 - 3) 0 (0 - 2)
Constipation 48     0.08
 Mean ± SD 0.5 ± 0.7 0.3 ± 0.5 0.3 ± 0.5
 median (range) 0 (0 - 3) 0 (0 - 2) 0 (0 - 2)
Defecation number (/ day) 49     0.85
 Mean ± SD 1.1 ± 1.0 1.0 ± 0.8 1.0 ± 0.7
 Median (range) 1 (0 - 4) 1 (0 - 4) 1 (0 - 4)
Epworth Sleep Scale 49     0.96
 Mean ± SD 6.3 ± 4.0 6.1 ± 4.2 6.0 ± 4.2
 Median (range) 6 (0 - 16) 5 (0 - 18) 5 (0 - 19)
  1. SD; standard deviation, n.s.; not significant (p > 0.05).
  2. aFriedman test.
  3. bPost-hoc nonparametric multiple comparison analysis was performed using Steel method after significant difference in assessment scores across multiple points was detected by Freidman test (p = 0.01).